Bellevue Life Sciences Acquisition Corp. Warrant
Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquire companies in the healthcare industry. The company was founded in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp… Read more
Bellevue Life Sciences Acquisition Corp. Warrant (BLACW) - Net Assets
Latest net assets as of June 2024: $15.15 Million USD
Based on the latest financial reports, Bellevue Life Sciences Acquisition Corp. Warrant (BLACW) has net assets worth $15.15 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($20.63 Million) and total liabilities ($5.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.15 Million |
| % of Total Assets | 73.4% |
| Annual Growth Rate | 2920.8% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Bellevue Life Sciences Acquisition Corp. Warrant - Net Assets Trend (2020–2023)
This chart illustrates how Bellevue Life Sciences Acquisition Corp. Warrant's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bellevue Life Sciences Acquisition Corp. Warrant (2020–2023)
The table below shows the annual net assets of Bellevue Life Sciences Acquisition Corp. Warrant from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $32.52 Million | +86800.07% |
| 2022-12-31 | $-37.51K | -1669.25% |
| 2021-12-31 | $-2.12K | -278.45% |
| 2020-12-31 | $1.19K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bellevue Life Sciences Acquisition Corp. Warrant's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 388319600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $36.43 Million | 112.01% |
| Total Equity | $32.52 Million | 100.00% |
Bellevue Life Sciences Acquisition Corp. Warrant Competitors by Market Cap
The table below lists competitors of Bellevue Life Sciences Acquisition Corp. Warrant ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Trail Blazer Capital Corp.
V:TBLZ-P
|
$470.24 |
|
Coro Energy PLC
LSE:CORO
|
$470.51 |
|
Verify Smart Corp
PINK:VSMR
|
$470.56 |
|
GWH-WT
NYSE:GWH-WT
|
$471.62 |
|
JMD Properties Inc
PINK:SLDX
|
$469.67 |
|
EYANG HOLDINGS
BE:4EY
|
$469.38 |
|
Asim Textile Mills Ltd
KAR:ASTM
|
$469.20 |
|
GKS GieKSa Katowice SA
WAR:GKS
|
$468.49 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bellevue Life Sciences Acquisition Corp. Warrant's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -37,508 to 32,519,461, a change of 32,556,969.
- Net income of 403,780 contributed positively to equity growth.
- Share repurchases of 35,995,728 reduced equity.
- New share issuances of 63,970,000 increased equity.
- Other factors increased equity by 4,178,917.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $403.78K | +1.24% |
| Share Repurchases | $36.00 Million | -110.69% |
| Share Issuances | $63.97 Million | +196.71% |
| Other Changes | $4.18 Million | +12.85% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Bellevue Life Sciences Acquisition Corp. Warrant's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 392.54x to 0.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.00 | $0.05 | x |
| 2021-12-31 | $0.00 | $0.05 | x |
| 2022-12-31 | $0.00 | $0.05 | x |
| 2023-12-31 | $5.78 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bellevue Life Sciences Acquisition Corp. Warrant utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.13x
- Recent ROE (1.24%) is above the historical average (0.41%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.10K |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.64K |
| 2023 | 1.24% | 0.00% | 0.00x | 1.13x | $-2.85 Million |
Industry Comparison
This section compares Bellevue Life Sciences Acquisition Corp. Warrant's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $36,677,338
- Average return on equity (ROE) among peers: -64.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bellevue Life Sciences Acquisition Corp. Warrant (BLACW) | $15.15 Million | 0.00% | 0.36x | $470.20 |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $-60.27K | 0.00% | 0.00x | $198.37 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $205.28 Million |
| Ares Acquisition Corporation II (AACT-UN) | $931.34 Million | 0.00% | 0.08x | $399.77 Million |
| AA Mission Acquisition Corp. (AAM-UN) | $-559.90 Million | 0.00% | 0.00x | $349.76 Million |
| Global Acquisitions Corporation (AASP) | $3.80 Million | -5.26% | 0.34x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $8.75K | -623.31% | 2.50x | $461.96K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $-8.52 Million | 0.00% | 0.00x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-501.57K | 0.00% | 0.00x | $13.62K |
| ACRO Biomedical Co Ltd (ACBM) | $685.87K | -17.12% | 0.46x | $30.04K |
| Huaizhong Health Group Inc (ADAD) | $-19.47K | 0.00% | 0.00x | $3.15K |